Alphabet, Tencent and Gilead Sciences are in line to achieve exits, after the vaccine developer filed to go public on the Nasdaq Global Market.

The NK cancer drug provider has filed to go public in an offering which would enable GC and its GC Labcell subsidiary to exit.

Autobio Diagnostics is set to exit the molecular diagnostic test provider through a purchase by women’s health-focused technology provider Hologic.

Schroder UK Public Private Trust, the rebranded fund previously led by Neil Woodford, has sold its shareholding in Carrick Therapeutics at a discount.

University of Oxford, OSI and Parkwalk Advisors all returned for Oxford Endovascular’s $10m series A round.

Oxford spinout Vaccitech, which developed the technology underlying the university’s covid vaccine, has filed for an offering on the Nasdaq Global Market.

Mass General Brigham’s AI Digital Innovation Fund has chipped into a $17.3m round for the healthcare data technology provider.

The oncology drug developer, backed by Bristol Myers Squibb, secured close to $144m in its IPO. This is an exit from a space that has seen much corporate support over the past decade.

Each Friday the Global Corporate Venturing Deal Net rounds up the week’s smaller deals and tracks the emerging companies accessing corporate funds.

Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.